Cellnovo mobile diabetes management system wins EU approval

23 November 2011

Cellnovo has received CE Mark approval for its diabetes management system built around mobile, wireless technology.

The system includes an insulin patch pump, a wireless, touchscreen handset with a built-in blood glucose monitor, and an extendable applications set.

The Cellnovo handset wirelessly receives and transmits real-time data to a portal for patients and caregivers to use. This means that patients no longer have the burden of keeping meticulous journals, and that the data collected is incredibly accurate and consistent, ensuring optimal monitoring and treatment of the disease.

 "This is Cellnovo's first step in a journey to bring this mobile diabetes management system to the world," says William McKeon, Chief Executive Officer of Cellnovo.

The Cellnovo diabetes management system

"Cellnovo has created the first insulin pump that brings innovation and combines form with function, essential qualities in a device that patients have to interact with 24/7," says Dr. Pratik Choudhary, Clinical Lecturer in Diabetes at King's College London.

Cellnovo's ground breaking technology means that diabetes therapies can now be managed more easily, accurately and intuitively. The patch pump is the smallest and most precise ever developed, and the touch screen, wireless handset is instantly familiar to those who have used other mobile devices such as Apple's iPhone.

"Cellnovo has combined advanced mobile and medical technology which may create a paradigm shift in diabetes care," says Irl B. Hirsch, Professor of Medicine, University of Washington, Seattle, USA. "For the multitude of patients who could benefit from pump therapy, Cellnovo could be a game-changer."

"The ability to see real-time data of patients who may be hundreds of miles away provides the opportunity to redefine our care model," says Dr. Mark Evans, Lecturer and Honorary Consultant at the Institute of Metabolic Science at the University of Cambridge.

Source: Cellnovo